Department of Rheumatology, The Third Affiliated Hospital of Sun Yat-sen University, Tianhe Road No 600, 510630, Guangzhou, China.
Rheumatol Int. 2011 Feb;31(2):233-8. doi: 10.1007/s00296-009-1313-9. Epub 2009 Dec 13.
The objectives of this study were to evaluate the reliability of Bath ankylosing spondylitis functional index (BASFI) and Bath ankylosing spondylitis disease activity index (BASDAI) in Chinese ankylosing spondylitis (AS) and undifferentiated spondyloarthropathy (USpA) patients. 664 AS patients by the revised New York criteria for AS and 252 USpA patients by the European Spondyloarthropathy Study Group criteria were enrolled. BASDAI and BASFI questionnaires were translated into Chinese. Participants were required to fill in BASFI and BASDAI questionnaires again after 24 h. Moreover, BASDAI and BASFI were compared in AS patients receiving Enbrel or infliximab before and after treatment. For AS group, BASDAI ICC: 0.9502 (95% CI: 0.9330-0.9502, α=0.9702), BASFI ICC: 0.9587 (95% CI: 0.9521-0.9645, α=0.9789). For USpA group, BASDAI ICC: 0.9530 (95% CI: 0.9402-0.9632, α=0.9760), BASFI ICC: 0.9900 (95% CI: 0.9871-0.9922, α=0.9950). In the AS group, disease duration, occipital wall distance, modified Schober test, chest expansion, ESR, and CRP showed significant correlation with BASDAI and BASFI (all P<0.01). In the USpA group, onset age, ESR, and CRP were significantly correlated with BASDAI (all P<0.05), while modified Schober test, ESR, and CRP were significantly associated with BASFI (all P<0.05). The change in BASDAI and BASFI via Enbrel or infliximab treatment showed a significant positive correlation (P<0.01). The two instruments have good reliability and reference value regarding the evaluation of patient's condition and anti-TNF-α treatment response.
本研究旨在评估 Bath 强直性脊柱炎功能指数（BASFI）和 Bath 强直性脊柱炎疾病活动指数（BASDAI）在中国人中强直性脊柱炎（AS）和未分化脊柱关节病（USpA）患者中的可靠性。本研究共纳入 664 例符合修订后的纽约 AS 诊断标准的 AS 患者和 252 例符合欧洲脊柱关节病研究组标准的 USpA 患者。BASDAI 和 BASFI 问卷被翻译成中文。要求参与者在 24 小时后再次填写 BASFI 和 BASDAI 问卷。此外，比较了接受依那西普或英夫利昔单抗治疗前后 AS 患者的 BASDAI 和 BASFI。对于 AS 组，BASDAI ICC：0.9502（95%CI：0.9330-0.9502，α=0.9702），BASFI ICC：0.9587（95%CI：0.9521-0.9645，α=0.9789）。对于 USpA 组，BASDAI ICC：0.9530（95%CI：0.9402-0.9632，α=0.9760），BASFI ICC：0.9900（95%CI：0.9871-0.9922，α=0.9950）。在 AS 组中，疾病持续时间、枕墙距离、改良 Schober 试验、胸廓扩张、ESR 和 CRP 与 BASDAI 和 BASFI 显著相关（均 P<0.01）。在 USpA 组中，发病年龄、ESR 和 CRP 与 BASDAI 显著相关（均 P<0.05），而改良 Schober 试验、ESR 和 CRP 与 BASFI 显著相关（均 P<0.05）。依那西普或英夫利昔单抗治疗后 BASDAI 和 BASFI 的变化呈显著正相关（P<0.01）。这两种工具在评估患者病情和抗 TNF-α 治疗反应方面具有良好的可靠性和参考价值。
Zotero 插件